Trial Overview
NCT05640843 | Memorial Sloan Kettering | PI: Urvi A. Shah, MD | Randomized, placebo-controlled | N=150 | Primary endpoint: Δ stool butyrate at 12 weeks | Population: MGUS/SMM patients not already following whole-foods plant-based diet
Key Findings (Pilot Data, ASH 2024)
Metabolic: 7% sustained BMI reduction at 1 year; improved fasting insulin; increased adiponectin-to-leptin ratio.
Microbiome: Increased alpha diversity; enrichment of butyrate-producing taxa; effects sustained post-intervention.
Inflammatory: Reduced CRP; reduced neutrophil count; increased CD14+ classical monocytes; reduced CD16+ non-classical monocytes.
Disease trajectory: Two patients demonstrated altered progression trajectory—first interventional evidence for dietary modification of MGUS/SMM course.
Vk*MYC mouse model: 40% non-progression on high-fiber diet (vs. 100% progression in controls); 2.5× increase in median PFS (30 vs. 12 weeks); increased IFN-γ+ T lymphocytes in bone marrow; reduced T-cell exhaustion markers.
Mechanistic Framework
Primary pathway: Dietary fiber → colonic fermentation → butyrate production → HDAC inhibition → NF-κB suppression → reduced pro-inflammatory cytokine expression → altered bone marrow microenvironment.
Secondary pathway (VSI addition): Dietary anthocyanins (C3G) → colonic bacterial β-glucosidase → protocatechuic acid (PCA) → IκB-α phosphorylation blockade → NF-κB suppression via distinct mechanism. Also Nrf2 activation for cytoprotective gene expression.
Evidence for microbiome dependency: Wang 2012 (Circ Res) demonstrated complete abolition of C3G cardiovascular benefit with antibiotic elimination of gut bacteria, and restoration of effect upon bacterial reconstitution. Definitive proof of microbial bioactivation requirement.
Cross-Feeding Guild Architecture
Butyrate production requires intact bacterial assembly line:
| Guild Role | Key Species | Function | If Absent |
|---|---|---|---|
| Primary degraders | Bacteroides, R. bromii, Bifidobacterium | Complex polysaccharide breakdown | Fiber passes unfermented |
| Acetate producers | Bifidobacterium spp. | Acetate as butyrate co-substrate | Butyrate pathway substrate-limited |
| Butyrate producers | F. prausnitzii, Roseburia, E. rectale | Final conversion via butyryl-CoA:acetate CoA-transferase | No therapeutic butyrate output |
| Hydrogen consumers | Methanogens, acetogens | Maintain fermentation thermodynamics | Gas accumulation, reduced efficiency |
| Habitat maintainers | Akkermansia muciniphila | Mucus layer integrity | Barrier dysfunction, aerobic drift |
Clinical implication: Fiber intervention efficacy depends on guild integrity. Patients with post-antibiotic dysbiosis, chemotherapy-induced damage, or long-term processed food diets may show no response or symptom worsening. Consider ecosystem assessment before aggressive fiber introduction.
Response Variability Predictors
Likely responders: Intact microbiome diversity; no recent antibiotic exposure; prior fiber tolerance; no significant bloating with fiber challenge.
Likely non-responders: Multiple antibiotic courses; chemotherapy exposure; prolonged low-fiber diet; significant bloating/gas with fiber; Proteobacteria predominance on testing.
For non-responders: Consider dual-pathway approach—exogenous sodium butyrate (300-600mg TID) to support colonocyte health while rebuilding endogenous production through gradual fiber introduction and targeted prebiotic protocols.
Oxygen Control Hypothesis
Colonocytes preferentially metabolize butyrate via β-oxidation, consuming O₂ and maintaining luminal hypoxia (<1% O₂). This anaerobic environment is required for strict anaerobe (butyrate producer) survival.
Aerobic drift cascade: Butyrate depletion → colonocyte fuel switch to glycolysis (Warburg effect) → reduced O₂ consumption → luminal oxygen rise → strict anaerobe die-off → facultative anaerobe bloom (Enterobacteriaceae) → self-reinforcing dysbiosis.
Clinical relevance: Explains why probiotic supplementation with strict anaerobes often fails—oxygenated environment prevents colonization. Ecosystem restoration requires addressing oxygen environment before introducing sensitive species.
MGRS-Specific Considerations
MGRS patients may benefit from intensified gut-focused intervention due to: (1) direct renal inflammation susceptible to NF-κB modulation; (2) chemotherapy-induced microbiome devastation creating vicious cycle; (3) limited alternative biomarkers—microbiome parameters may provide additional monitoring.
Suggested protocol: Baseline microbiome assessment if available; butyrate scaffolding during active treatment; aggressive fermented food introduction post-treatment; functional omnivory as long-term maintenance.
Practical Implementation
Dietary targets: 30+ diverse plant foods/week; daily fermented food; resistant starch via cook-cool-reheat protocol; anthocyanin-rich foods (black rice, purple sweet potato, berries) 3-4x/week; fatty fish 2-3x/week for omega-3s that support microbiome diversity.
Functional omnivory vs. NUTRIVENTION protocol: Trial uses vegan protocol for variable isolation. Long-term implementation benefits from functional omnivory—fermented dairy (kefir, traditional yogurt), bone broth/collagen, fatty fish—providing nutrients that support guild function directly.
Monitoring: Consider serial CRP, neutrophil counts, monocyte subsets for inflammation tracking. Stool butyrate if available. Clinical response to fiber introduction as functional guild assessment.
Key References
- ClinicalTrials.gov. NCT05640843: NUTRIVENTION-3 Study. Memorial Sloan Kettering Cancer Center.
- Shah UA, et al. Plant-Based Diet and Microbiome in MGUS and SMM. Blood. 2024; ASH Annual Meeting.
- Litvak Y, et al. Colonocyte metabolism shapes the gut microbiota. Science. 2018;362(6418):eaat9076.
- Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017;19(1):29-41.
- Duncan SH, et al. Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria. Appl Environ Microbiol. 2002;68(10):5186-90.
- Wang D, et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ Res. 2012;111:967-81.
- Hanske L, et al. Contribution of gut bacteria to the metabolism of cyanidin 3-glucoside in human microbiota-associated rats. Br J Nutr. 2013;109(8):1433-41.
- Czank C, et al. Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a ¹³C-tracer study. Am J Clin Nutr. 2013;97(5):995-1003.
- Rahman S, et al. Health benefits of cyanidin-3-glucoside as a potent modulator of Nrf2-mediated oxidative stress. Inflammopharmacology. 2021;29:907-923.
- Silva KR, et al. Milk kefir alters fecal microbiota impacting gut and brain health. J Nutr Biochem. 2024.